Avidity Biosciences, Inc.
RNA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $3,681 | $3,815 | $3,737 |
| - Cash | $350 | $244 | $254 | $220 |
| + Debt | $46 | $5 | $6 | $7 |
| Enterprise Value | – | $3,442 | $3,567 | $3,524 |
| Revenue | $12 | $4 | $2 | $3 |
| % Growth | 224.3% | 144.6% | -47.1% | – |
| Gross Profit | $12 | -$134 | $2 | $3 |
| % Margin | 100% | -3,490.5% | 100% | 100% |
| EBITDA | -$173 | -$170 | -$131 | -$120 |
| % Margin | -1,389.9% | -4,427.6% | -8,311% | -4,044.8% |
| Net Income | -$174 | -$157 | -$116 | -$102 |
| % Margin | -1,398.3% | -4,089.3% | -7,360% | -3,439.5% |
| EPS Diluted | -1.27 | -1.21 | -0.9 | -0.8 |
| % Growth | -5% | -34.4% | -12.5% | – |
| Operating Cash Flow | -$156 | -$200 | -$125 | -$100 |
| Capital Expenditures | -$4 | -$3 | -$4 | -$4 |
| Free Cash Flow | -$160 | -$203 | -$129 | -$104 |